Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
With
Novartis
The administration of Zometa in short intervals has been implied to be more potent in maximizing its antitumor and antiangiogenesis effects, while dosing every four weeks is an appropriate strategy for the prevention and management of bone metastases. This study was designed to explore the relationship between dosing of Zometa and level of circulating VEGF.
Negative serum pregnancy test for women with childbearing potential
Good conditions for infusion and willing to undergo phlebotomy during the whole study
Have ceased anti-tumor treatment including chemotherapy, endocrinotherapy and bio-targeted therapy for over 28 days
You may not be if
Pregnant or lactating females
History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety
Active or uncontrolled infection
Current active dental problems including infection of the teeth or jawbone (maxilla or mandible); dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw (ONJ); or exposed bone in the mouth; or slow healing after dental procedures
Recent (within 6 weeks of Randomization) or planned dental or jaw surgery (e.g. extraction, implants)
Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure
Concomitant with liver, brain or symptomatic lung metastases (symptoms such as hemoptysis, severe cough and shortness of breath)
Accepted radiotherapy for solitary bone disease within 30 days before study
Previous treatment with other bisphosphonates or radionuclides within one month before study
Known hypersensitivity to bisphosphonates
History of treatment with calcitonin, gallium nitrate or mithracin within 14 days before study.
